Bio Green Med Solution | 10-Q: FY2025 Q3 Revenue: USD 81 K

Revenue: As of FY2025 Q3, the actual value is USD 81 K.

EPS: As of FY2025 Q3, the actual value is USD -1.31.

EBIT: As of FY2025 Q3, the actual value is USD -1.001 M.

Segment Revenue

• Product Revenue - Fire Safety: $81,000 for the three and nine months ended September 30, 2025, compared to $0 for the same periods in 2024. This revenue is attributed to the sales of fire safety equipment and services within the newly acquired Malaysian-based subsidiary, Fitters Sdn. Bhd.

Operational Metrics

• Net Loss: - $2,387,000 for the nine months ended September 30, 2025, compared to - $8,160,000 for the same period in 2024, reflecting a decrease in net loss by $5,773,000.
• Operating Loss: - $7,345,000 for the nine months ended September 30, 2025, compared to - $10,176,000 for the same period in 2024.
• General and Administrative Expenses: $6,467,000 for the nine months ended September 30, 2025, compared to $4,444,000 for the same period in 2024, an increase of $2,023,000 primarily due to one-time costs associated with changes of control.
• Research and Development Expenses: $895,000 for the nine months ended September 30, 2025, compared to $5,775,000 for the same period in 2024, a decrease of $4,880,000 due to the liquidation of Cyclacel Limited and the sale of the plogosertib asset.

Cash Flow

• Net Cash Used in Operating Activities: - $4,737,000 for the nine months ended September 30, 2025, compared to - $6,634,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $5,523,000 for the nine months ended September 30, 2025, primarily from the issuance of preferred stock under Securities Purchase Agreements.

Unique Metrics

• Gain on Deconsolidation of Subsidiary: $4,947,000 gain recognized due to the deconsolidation of Cyclacel Limited following its liquidation.

Future Outlook and Strategy

• Core Business Focus: The company plans to focus on the development of its fire safety segment through the integration of Fitters Sdn. Bhd., expecting growth in revenues during the fourth quarter of 2025.
• Non-Core Business: The company has sold its bio-pharmaceutical asset, plogosertib, for $300,000, with a potential milestone payment of $170,000, and does not expect to incur material research and development expenditures prospectively.
• Priority: The company is exploring ways to raise additional capital through private equity financing or strategic transactions to address liquidity concerns and continue operations.